The Internet site that you are about to view is an online educational resource intended
for medical professionals based in the United Kingdom only. The site contains up-to-date
information on The Binding Site’s products, and may therefore contain information on
medical devices and other products or uses of those products that are not approved or
cleared in other countries or regions.
This site is not intended to promote off label use of any of The Binding Site’s
products. To obtain appropriate product information for your country of residence,
please contact your local distributor.
The recent availability of assays that quantitatively measure immunoglobulin heavy/light chain (Hevylite®, HLC) pairs (Chapter 9) may provide an extra test for the diagnosis, prognosis and monitoring of AL amyloidosis .
What is the frequency of an abnormal κ/λ sFLC ratio in AL amyloidosis?
How frequently should sFLCs be assessed in patients undergoing treatment for AL amyloidosis?
What are the major prognostic factors for AL amyloidosis outcome?
An abnormal κ/λ sFLC ratio is found in 75 - 98% of patients (Section 28.2).
sFLCs are usually assessed prior to every cycle of chemotherapy. British guidelines recommend monitoring response to treatment with sFLCs after each cycle of chemotherapy and every 1 - 3 months thereafter, with the aim of switching to an alternative regimen as soon as the current one is proving ineffectual, which may be assessed after three cycles of therapy or earlier in cardiac patients (Section 28.6.3)
1. Wechalekar AD, Young P, Wassef N, Gillmore JD, Gibbs SDJ, Pinney JH et al. Normal heavy/light chain (HLC) and free light chain (FLC) ratios are associated with prolonged survival in patients with systemic AL amyloidosis. Presented at XIII International Symposium on Amyloidosis 2012;PB30a
2. Sachchithanantham S, Berlanga O, Harding S, Wassef N, Mahmood S, Sayeed R et al. Heavy/light chain-pair suppression as a novel marker of poor outcomes in systemic AL amyloidosis. Presented at XIV International Symposium on Amyloidosis 2014;PB-34a